David A Braun
Overview
Explore the profile of David A Braun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
2721
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang Q, Braun D, Clauser K, Ramesh V, Shirole N, Duke-Cohan J, et al.
Cell
. 2025 Mar;
PMID: 40023154
Clear cell renal cell carcinoma (ccRCC), despite having a low mutational burden, is considered immunogenic because it occasionally undergoes spontaneous regressions and often responds to immunotherapies. The signature lesion in...
2.
Hugaboom M, Wirth L, Street K, Ruthen N, Jegede O, Schindler N, et al.
Cancer Discov
. 2025 Feb;
PMID: 39992403
Immune checkpoint inhibitors (ICI) targeting the PD-1 pathway have transformed treatment of advanced renal cell carcinoma (RCC), but mechanisms underlying therapeutic response remain largely unknown. Herein, we perform transcriptomic analysis...
3.
Braun D, Moranzoni G, Chea V, McGregor B, Blass E, Tu C, et al.
Nature
. 2025 Feb;
639(8054):474-482.
PMID: 39910301
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens. However, whether such responses can target cancer driver mutations, lead to immune recognition of a patient's tumour and...
4.
Jammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A, et al.
Nat Cancer
. 2025 Jan;
6(2):372-384.
PMID: 39789182
Immune checkpoint inhibitors can lead to 'exceptional', durable responses in a subset of persons. However, the molecular basis of exceptional response (ER) to immunotherapy in metastatic clear cell renal cell...
5.
Iorgulescu J, Blewett T, Xiong K, Crnjac A, Liu R, Sridhar S, et al.
Clin Chem
. 2025 Jan;
71(1):215-225.
PMID: 39749509
Background: Minimally invasive molecular profiling using cell-free DNA (cfDNA) is increasingly important to the management of cancer patients; however, low sensitivity remains a major limitation, particularly for brain tumor patients....
6.
Schoenfeld D, Djureinovic D, Su D, Zhang L, Lu B, Kamga L, et al.
JCI Insight
. 2024 Nov;
10(1).
PMID: 39561007
The cytokine IL-18 has immunostimulatory effects but is negatively regulated by a secreted binding protein, IL-18BP, that limits IL-18's anticancer efficacy. A decoy-resistant form of IL-18 (DR-18) that avoids sequestration...
7.
8.
Figiel S, Bates A, Braun D, Eapen R, Eckstein M, Manley B, et al.
Eur Urol
. 2024 Sep;
87(1):8-14.
PMID: 39227262
New spatial molecular technologies are poised to transform our understanding and treatment of urological cancers. By mapping the spatial molecular architecture of tumours, these platforms uncover the complex heterogeneity within...
9.
Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Diaz-Fernandez P, et al.
Nat Biotechnol
. 2024 Aug;
PMID: 39169264
T cell alloreactivity against minor histocompatibility antigens (mHAgs)-polymorphic peptides resulting from donor-recipient (D-R) disparity at sites of genetic polymorphisms-is at the core of the therapeutic effect of allogeneic hematopoietic cell...
10.
El Zarif T, Semaan K, Xie W, Eid M, Zarba M, Issa W, et al.
Eur Urol
. 2024 Aug;
86(6):503-512.
PMID: 39147674
Background And Objective: Adjuvant pembrolizumab significantly improved overall survival (OS) in renal cell carcinoma (RCC), but real-world data on sequential treatment are scarce. We sought to evaluate the clinical outcomes...